US-guided Nanosecond Pulsed Electric Field Ablation of Low-risk Papillary Thyroid Microcarcinoma (PTMC): Interim Results of a Prospective Multicenter Study
Authors' conclusion
nsPEF ablation under general anesthesia for low-risk PTMC is effective and safe, with the only major complication being transient thyrotoxicosis in more than 50% of patients, which might be caused by the release of thyroid hormones into the bloodstream because of irreversible electroporation. It appears to offer better absorption of the ablated lesions in the short term, potentially increasing its clinical use. Further short- and long-term study is needed.
Study context
- Population
- Consecutive low-risk patients with PTMC, 6 hospitals in China, September 2022 to September 2024; median age 38 years (IQR 32–47), 58 females
- Participants
- 85 PTMCs
- Outcome
- Efficacy and safety of nsPEF ablation: technical success (contrast-enhanced US immediately after ablation, ablation zone exceeding tumor edge) and therapeutic efficacy
- Follow-up
- 1-, 3-, 6- and 12-month follow-up
Methodological details6 hospitals in China, interim results
- 6 hospitals in China
- Interim results
Main finding
As reported in the abstract
All achieved successful nanosecond pulsed electric field (nsPEF) ablation
85
Median tumor volume at 1, 3, 6, 12 months
0.109, 0.054, 0.020, 0.000 mL
Median volume reduction ratio at 1, 3, 6, 12 months
−124.0%, −4.8%, 63.5%, 100%
Complete disappearance at 12 months
88.0%
66/75
Observational data: associations, not effects.
Further findings
Recurrence and metastasis · during follow-up
- No recurrent tumors, cervical lymph node metastasis or distant metastasis
Safety
- Patients with transient thyrotoxicosis
- 56 (65.9%)
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →